Biolife Solutions, Inc. (NASDAQ: BLFS) has recently appointed Cathy Coste as Director and Audit Committee Chair, increasing the board membership to seven. Ms. Coste brings over four decades of experience as a senior executive, with substantial expertise in audits, risk and controls, and compliance. She retired from Deloitte in 2020, where she served as a senior partner and life sciences industry executive leader for over 30 years.
Having transitioned to a pure-play enabler of cell and gene therapies, Biolife is well-positioned for revenue growth and sustained profitability. Ms. Coste's appointment comes at an exciting and pivotal time for the company.
Ms. Coste currently serves as the audit committee chair for Biomerica, Inc., Minerva Surgical, Inc., and Renalytix plc. She holds a B.A. in Business Administration-Accounting from California State University, Hayward, and has completed Harvard Business School's Corporate Director's Certificate Program. She is also a licensed Certified Public Accountant.
Biolife Solutions is a leading supplier of cell processing tools and services for the cell and gene therapy market, facilitating the commercialization of new therapies by providing solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. Today the company's shares have moved 5.7% to a price of $26.41. Check out the company's full 8-K submission here.
